Previous 10 | Next 10 |
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved...
Interpace Biosciences ( OTCQX:IDXG ) on Wednesday said it had closed the sale of its pharma services business to Flagship Biosciences. IDXG CEO Thomas Burnell said with the completion of the deal, the company's operating cash flow is expected to improve by nearly $5M annually....
Interpace Transitions to focused Molecular Diagnostics Business Disposition of Pharma Services Expected to I mprove Operating Cash Flow by nearly $ 5 million A nnually PARSI...
Interpace Biosciences press release (OTCQX:IDXG): Q1 GAAP EPS of -$0.53. Revenue of $10.38M (+5.6% Y/Y). March 31, 2022 cash balance was $2.9 million, net of restricted cash and May 12, 2022 cash balance was $3.3 million, net of restricted cash. For further details see: Interpace Biosci...
PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quar...
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tools f...
Interpace Biosciences press release (OTCQX:IDXG): Q4 GAAP EPS of -$0.89. Revenue of $10.86M (+12.5% Y/Y). For further details see: Interpace Biosciences GAAP EPS of -$0.89, revenue of $10.86M
PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial ...
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the National Correct Coding Initiative (NCCI) program issued a respons...
Peter Kamin's purchase of IAA shares last week was the first insider purchase at IAA, since the company was spun off from KAR Auction Services in June 2019. IAA sports gross margin approaching 40%, EBITDA margin of 30%, and net income margin of 16%. Multiple insiders of IAA have e...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...